Varicose Vein Treatment Devices Market

Varicose Vein Treatment Devices Market Summary:

As per the Transpire Insight Analysis, the Varicose Vein Treatment Devices Market size is estimated at USD 1.81 Billion in 2025 and is anticipated to reach USD 3.43 Billion by 2033, growing at a CAGR of 8.32% from 2026 to 2033.

The market provides laser, radiofrequency, sclerotherapy, occlusion devices, and compression that allow clinicians to seal or reduce malfunctioning leg veins, predominantly in non-hospital outpatient environments instead of open stripping. Over the last three to five years, care has shifted towards image-guided, minimally invasive procedures; guidelines recommend endovenous ablation rather than ligation and stripping for eligible symptomatic saphenous-vein reflux. A structural shift is value shifting away from capital equipment toward single-use fibres, catheters and procedure kits, increasing recurrent revenue. A recent real-world trigger was the SCAI chronic venous disease guidance, which recommends ablation with conservative care for eligible symptomatic small and great saphenous vein reflux, adding to clinician confidence in intervention-dependent care. Population ageing, inactivity and obesity expand the treatable population; increased ultrasound planning and heat regulation decrease recovery, shifting procedures towards outpatient settings and increasing equipment productivity, paper cost and adoption by hospitals, specialist clinics and ambulatory units.

Varicose Vein Treatment Devices Market Size & Forecast:

• Market Size 2025: USD 1.81 Billion
• Expected Market Value (2033): USD 3.43 Billion
• Forecast CAGR (2026–2033): 8.32%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific
• Key Company Profiles: Medtronic, Boston Scientific, AngioDynamics, Biolitec, Teleflex, Abbott, Merit Medical Systems, Cook Medical, BD, Olympus, LSO Medical, VVT Medical, Sciton, Alma Lasers, Dornier MedTech.

Key Varicose Vein Treatment Devices Market Insights:

The market is shifting from the traditional energy generator to an integrated platform that includes mapping, delivery, disposables and follow-up. Today, installed-base trust leads, lower-cost systems, nonthermal therapy, and workflow data lead tomorrow.

• North America accounts for 42%, and Medtronic's ClosureFast ecosystem supports catheter-led ablation and clinic familiarity.

• Europe accounts for 31% of the contribution; Biolitec distinguishes laser systems by wavelength, fibre design, and precision.

• Asia Pacific accounts for 21% of the market and is growing at 12.6% CAGR; Merit's ClariVein OC contributes to nonthermal access via distributors.

• Latin America accounts for 3% of the market, and VenaCure kits by AngioDynamics allow for the use of laser in the region via distributors.

• The Middle East and Africa account for 3%, and Teleflex and Cook can expand via training and referral networks.

• Radiofrequency has 23%; Boston Scientific's VenaSeal is taking a step forward with nonthermal closure competition.

• Sclerotherapy has 15% scalability; BD and Merit can scale consumable-led office procedures.

• Venous Closure Systems represents 11%, while the others, VVT Medical and Boston Scientific, represent catheter innovation and consolidation.

• Compression Therapy has 7%, while Sciton, Alma, and LSO can link up with digital follow-up of care.

What are the Key Drivers, Restraints, and Opportunities in the Varicose Vein Treatment Devices Market?

Driver:

Outpatient reimbursement and clinical preference for endovenous ablation are diverting cases from hospital stripping. The catalyst is the SVS/AVF/AVLS instruction, which calls for endovenous ablation in candidates for treatment of symptomatic axial reflux. As laser and radiofrequency interventions need minimal operating-room resources and support accelerated recovery, clinics may number more cases in each session, increasing console utilisation and recurring probe or fibre income. Growth also proves advantageous to vendors in terms of replacement probes, service agreements and standardised kits.

Restraint:

Unequal availability of duplex ultrasound, trained vein specialists and reimbursement continues to constrain conversion. This remains a structural problem as device performance is operator-dependent, local referral pathways and capital costs must be paid up-front, and smaller hospitals cannot subsidise dedicated systems on low case volumes. Delays in diagnosis, prolonged device procurement cycles, and centralisation of adoption in metropolitan providers.

Opportunity:

Integrated lower-cost systems can make it more affordable. Using AI-guided ultrasound location, reusable consoles with disposable procedure kits, and mobile outreach units could enable regional hospitals to triage and manage patients on site. Asia-Pacific producers and distributors could combine lightweight radiofrequency platforms with remote guidance, in turn turning underserved secondary cities into new procedure sites and safeguarding consumables-centric revenue. On-site service providers and training of clinicians could further mitigate downtime and confidence obstacles.

What Has the Impact of Artificial Intelligence Been on the Varicose Vein Treatment Devices Market?

Artificial intelligence influences this market mainly in the interpretation of duplex ultrasound, the planning of therapy and follow-up rather than the device itself. Computer-vision algorithms are able to segment superficial veins, detect reflux patterns, measure diameters and highlight anatomy requiring specialist review. This standardises and expedites pre-procedure mapping and labelling. Machine-learning algorithms can combine data from ultrasound images, symptoms and clinical history to predict the probability of treatment success, recurrence or need for escalation; hence, aid clinicians to choose laser, radiofrequency, sclerotherapy or surveillance. Once in the operating theatre, image and data processing can improve catheter placement, treatment length and energy dose; post-procedure, automated re-analysis of images can determine where residual reflux is likely. A 2025 review of AI applications in venous diseases found 90% precision and more than halved ultrasound analysis time, despite a paucity of evidence beyond validation cohorts. However, integration remains the challenge, including limited and biased data, explainability issues, security, changes to existing pathways, and regulatory approval; so AI increases efficiency and reliability initially, with autonomous treatment being further off.

In August 2026,Vexev secured $6 million in new funding to accelerate the United States commercialization and FDA clearance of its AI-powered robotic ultrasound platform, VxWave. This investment helps expand access to standardized vascular imaging after clinical trials demonstrated a 94% scanning success rate for autonomous acquisition by nonspecialist staff.

https://www.vexev.com/press/2026-fundraise-us

Key Varicose Vein Treatment Devices Market Trends:

The market is moving from hospital surgical procedures to repeatable, image-guided outpatient procedures. The strategic value is not just quicker recovery; it is a scalable console, disposable kit, software, and trained operator ecosystem.

• Endovenous ablation has replaced stripping for appropriate reflux over the last few years, resulting in an increased investment in outpatient consumables and equipment.
• Recurring supplier revenue is being enhanced as laser platforms are maturing from standalone capital equipment to a fibre-and-console ecosystem.
• The radiofrequency systems are getting noticed due to consistent thermal delivery, shorter workflows, and an 11.8% projected CAGR provided in the market data.
• Ultrasound is emerging from its role as a gatekeeper for diagnosis to becoming an intra-procedural navigation layer for mapping, catheter placement, and treatment verification.
• Vein clinics and ambulatory centres are accepting cases from hospitals, moving to purchase smaller systems, kits, and service responsiveness.
• Beyond heat-based ablation, manufacturers are working on nonthermal and focused-ultrasound alternatives, expanding choice; Sonovein's U.S. pivotal pathway is a case in point.
• Strategically, disposable components are gaining importance due to the focus on infection control, rapid turnover, and predictable procedure costs.
• AI-assisted image analysis is increasingly being adopted for actual workflows, but now the ability to validate and interoperate sets the standards for credible vendors.

Varicose Vein Treatment Devices Market Segmentation

By Product Type:

Endovenous Laser Devices are the volume leader at 41% share, by virtue of a 'best-of-both-worlds' argument: fibre-based ablation, outpatient recovery, and comfort level with the device. Radiofrequency Ablation Devices comprise 23% share and have a robust logic for growth: controlled circumferential heat, simple protocols, and vendor clinic preferences will drive the 11.8% CAGR. Sclerotherapy Devices comprise 15%, maintaining a place in smaller/superficial veins; Venous Closure Systems comprise 11%, with growth potential for a nonthermal firm; Compression Therapy Devices comprise 7%, as adjunct rather than curative; and Others comprise 3%, with experimental upside.

By Procedure Type:

Minimally Invasive Procedures lie at the heart since image guidance, local anaesthesia and early discharge all enhance capacity economics. Surgical Procedures will be needed when anatomy is not suitable for endovenous treatment. Ultrasound-guided Procedures are becoming more prominent by enhancing selection, accuracy, and follow-up; Others are tailored for specific cases.

By End User:

Hospitals continue to be relevant for complex referrals. Specialty Vein Clinics are quick to take up new devices because high case density provides payback. As outpatient volume increases, Ambulatory Surgical Centers are expected to increase. Dermatology Clinics will extend into cosmetic and spider-vein pathways while others target small practices.

By Application:

The Great Saphenous Vein proceeds as axial reflux ensures a consistent ablation requirement. Small Saphenous and Perforator Veins benefit from individualised mapping, giving a lucrative planning potential. Spider Veins are best treated with sclerotherapy and result in cosmetic improvements; others present a niche anatomy.

By Distribution Channel:

Capital equipment acquisitions, driven by manufacturer relations and institutional buying from direct sales and hospital purchasing. Medical Distributors increase geographic coverage, especially across fragmented US healthcare markets. Online Medical Suppliers gain market share in accessories and compression products, while Other channels are more local and smaller scale, targeting other specialist needs.

What are the Key Use Cases Driving the Varicose Vein Treatment Devices Market?

The core use case is image-guided closure of refluxing GSVs, which is similar to the top-selling 41% of the endovenous Laser Devices segment. Endovenous laser fibres and ultrasound mapping are used as an alternative to stripping, which leads to reduced theatre time and earlier resumption of normal activity.

Expanding indications include radiofrequency ablation devices for Small Saphenous and selected perforator-vein disease, whose controlled energy and repeatable protocols support speciality-clinic throughput. Sclerotherapy Devices for spider veins and residual tributaries expand treatment to vessels beyond major axial vessels.

Emerging use cases synergistically combine AI-enabled ultrasound triage with mobile or ambulatory services, allowing earlier referral, remote specialist analysis, and subsequent follow-up surveillance. Focused-ultrasound systems like Sonovein offer a future nonthermal route if key data and regulatory approval translate into clinical adoption.

Which Regions are Driving the Varicose Vein Treatment Devices Market Growth?

North America accounts for 42% of the market, with diagnosis, specialist density, and outpatient reimbursement enabling a quick referral to procedure conversion. The country has the infrastructural elements in place, such as duplex ultrasound, trained operators and supply channels, and a shifting payment policy towards office-based treatment favouring quick recovery, making it ready to adopt premium devices. North America's early leadership is corroborated by market research identifying it as the largest treatment market. In June 2026,Medtroniccompleted its acquisition of Scientia Vascular for $550 million, expanding advanced neurovascular access capabilities and therapeutic portfolios.

Europe achieved 31% but lags North America while being backed by vascular societies, universal-care infrastructure and wide experience with endovenous treatment. Stability is assured by standardised treatment pathways, availability of cross-border devices and an ageing population. Sustainability is overseen by cost controls and more stringent purchasing processes, delaying the launch of systems but encouraging long-lasting, effective systems. Manufacturers thus focus on evidence, cost per procedure, and compatibility with public hospitals.

In April 2026, InVera Medical announced FDA 510(k) clearance for the InVera infusion device to treat chronic venous disease. This approval expands minimally invasive treatment options across the United States and the European Union.

Asia Pacific at 21% is the fastest-growing region with a 12.6% CAGR. Urban speciality clinics, med-tourism centres, distributor investment, and improved access to ultrasound have recently squeezed diagnosis and training bottlenecks. Growth is spreading from the capitals into second- and third-tier cities, where smaller compact consoles and remote mentoring boost utilization. The opportunity is in local servicing, financing, and education combined with low-cost equipment and repeat disposable kits and mounting confidence to refer.

In May 2026,iSono Health announced the commercial launch of ATUSA, a wearable, FDA-cleared automated breast ultrasound system designed to capture full 3D volumes in two minutes and scale decentralized screening access.

Who are the Key Players in the Varicose Vein Treatment Devices Market, and how do they compete?

The competitive battle is based on three axes, which are suited to energy-based effectiveness, procedural simplification, and economics. In general, large medtech groups compete on broad vascular device portfolios and hospital relationships, while specialist manufacturers differentiate on laser wavelength, catheter design and targeted venous care applications. The battleground is moving to outpatient efficiency, nonthermal closure and consumables-centred recurring revenues.

The economics of the battleground case flow are predictable closure, short setup, education and predictable disposable income. The growth is happening more through dealers, clinical education, reimbursement data and the supply of consumables, not just local geographic sales force coverage and clinicians. The industry players are Medtronic, Boston Scientific, AngioDynamics, Teleflex, Merit, and the laser companies. Medtronic pairs scale with ClosureFast familiarity and clinic links. Boston Scientific uses portfolio innovation, VenaSeal, along with acquisition-led growth. AngioDynamics relies on VenaCure EVLT kits and distributors, while Biolitec and Dornier MedTech compete on laser engineering and fibre accuracy. Teleflex and Cook leverage vascular-access experience and sourcing scale. Merit aims for speciality innovation with ClariVein and Asia-Pacific presence. Abbott and BD are utilising cardiovascular adjuncts, cross-pollination, and tenders. Olympus, Sciton, and Alma focus on imaging, office-based, and aesthetic markets. LSO is seeking a dedicated laser market with broad-based competition. VVT Medical is addressing this through agile catheter innovation, regional partnerships, and low-cost deployment.

Key Players are:

• Medtronic
• Boston Scientific
• AngioDynamics
• Biolitec
• Teleflex
• Abbott
• Merit Medical Systems
• Cook Medical
• BD
• Olympus
• LSO Medical
• VVT Medical
• Sciton
• Alma Lasers
• Dornier MedTech

Recent Development News

In January 2026, Boston Scientific announced the acquisition of Penumbra in a transaction valued at approximately USD 11 billion. This strategic medical device integration expands the company's interventional and peripheral vascular treatment portfolio, significantly augmenting its clinical capabilities in minimally invasive vein therapies and deep venous obstruction procedures.

Source: https://news.bostonscientific.com

What Strategic Insights Define the Future of the Varicose Vein Treatment Devices Market?

The future market is moving toward outpatient, data-enabled vein treatment where disposables, mapping and service arrangements trump console sales in the coming decade. The key benefit will transition from energy delivery to reproducible occlusion, speed to train, and reimbursement evidence. Datasets may not be shared by AI and ultrasound equipment, causing workflow conflicts, validation shortfalls and cyber exposure risks. And commoditisation may undermine premium prices before clinicians fully trust clinical outcomes. The new game-changer is a vein-care platform integrating small RF or laser devices, AI-determined mapping, remote proctoring and longitudinal follow-up. Asia Pacific has the most promising track because its 21% share and 12.6% CAGR reflect existing and rising demand and capacity. Vendors need to localise service and credit, develop open protocols and data standards, and focus on economics of procedures rather than hardware wins. Collaborations with clinics, channels and education bodies can also drive adoption and reduce operator variation. Nonthermal systems such as Sonovein demonstrate the future frontier if regulatory dossier evidence continues to grow.

Key Segmentations are:

By Product Type

• Endovenous Laser Devices
• Radiofrequency Ablation Devices
• Sclerotherapy Devices
• Venous Closure Systems
• Compression Therapy Devices
• Others

By Procedure Type

• Minimally Invasive Procedures
• Surgical Procedures
• Ultrasound-guided Procedures
• Others

By End User

• Hospitals
• Specialty Vein Clinics
• Ambulatory Surgical Centers
• Dermatology Clinics
• Others

By Application

• Great Saphenous Vein
• Small Saphenous Vein
• Perforator Veins
• Spider Veins
• Others

By Distribution Channel

• Direct Sales
• Medical Distributors
• Hospital Procurement
• Online Medical Suppliers
• Others

Regional Outlook

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• Japan
• China
• Australia & New Zealand
• South Korea
• India
• Rest of Asia Pacific

South America

• Brazil
• Argentina
• Rest of South America

Middle East & Africa

• Saudi Arabia
• United Arab Emirates
• South Africa
• Rest of the Middle East & Africa